紫杉醇联合卡铂对比口服尿嘧啶替加氟辅助治疗完全切除NSCLC的多中心随机对照研究
该多中心开放标签随机对照研究纳入402例病理IB-IIIA期完全切除NSCLC患者,比较紫杉醇联合卡铂四周期与口服UFT两年的辅助化疗效果。中位随访6.5年,两组5年总生存率和无复发生存率均无显著差异,但紫杉醇联合卡铂组任何级别和4级毒性显著更高。
要点
- 紫杉醇联合卡铂辅助化疗的生存获益不优于口服UFT。
- 两组5年总生存率和无复发生存率均无显著差异。
- 紫杉醇联合卡铂组任何级别和4级毒性显著高于UFT组。
核心结论
- 在完全切除的IB-IIIA期NSCLC患者中,紫杉醇联合卡铂辅助化疗的生存获益不优于口服UFT。
主要发现
- 中位随访6.5年,A组5年总生存率70%(95%CI 63-76),B组73%(95%CI 66-78),HR=0.92(95%CI 0.55-1.41),p=0.69。
- A组5年无复发生存率56%,B组57%,HR=0.92(95%CI 0.63-1.34),p=0.50。
- A组任何级别毒性发生率95.7%,4级毒性22.1%;B组分别为76.5%和1.0%,两组比较p<0.0001。
- 两组均无治疗相关死亡。
临床怎么用
- 对于完全切除的IB-IIIA期NSCLC,紫杉醇联合卡铂辅助化疗未显示优于口服UFT的生存获益,且毒性更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We conducted a randomized controlled study to compare the survival benefit of paclitaxel plus carboplatin and oral uracil-tegafur (UFT) as adjuvant chemotherapy in resected NSCLC. METHODS: In an open-label multicenter trial, patients with pathological stage IB to IIIA NSCLC were randomized into a group receiving paclitaxel (175 mg/m2) plus carboplatin (area under the curve 5) every 3 weeks for four cycles (arm A) or a group receiving orally administered UFT (250 mg/m2) daily for 2 years (arm B). The primary and secondary end points were overall survival and relapse-free survival and toxicity, respectively. RESULTS: Between November 2004 and November 2010, 402 patients from 40 institutions were included (201 in each arm). The median follow-up period was 6.5 years. The 5-year overall survival rate was 70% (95% confidential interval [CI]: 63-76] in arm A versus 73% (95% CI: 66-78) in arm B (hazard ratio = 0.92, 95% CI: 0.55-1.41, p = 0.69). There was no significant difference in the 5-year relapse-free survival rate between arms A and B (56% versus 57% [hazard ratio = 0.92, 95% CI: 0.63-1.34, p = 0.50]). Toxicities were well tolerated and there was no treatment-related death. Toxicities of any grade or grade 4 were significantly more frequent in the paclitaxel plus carboplatin group (95.7% and 22.1%, respectively) than in the UFT group (76.5% and 1.0%, respectively [p < 0.0001 in both]). CONCLUSIONS: As adjuvant chemotherapy, paclitaxel plus carboplatin was no better than UFT in terms of survival among patients with stage IB to IIIA NSCLC tumors who underwent complete resection (UMIN000000810).
引用
- Toyooka S, Okumura N, Nakamura H, et al. A Multicenter Randomized Controlled Study of Paclitaxel plus Carboplatin versus Oral Uracil-Tegafur as the Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 29505900. doi:10.1016/j.jtho.2018.02.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。